Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
BPBiophytis S.A. logo

Biophytis S.A. (BPTS)

NASDAQ Capital Market · Currency in USD
$8.22 ▼ -1.28 (-13.47%)
At close: Apr 25, 4:00 PM ET. Market closed.

Summary

Previous Close
$9.50
Open
$8.24
Day's Range
$8.05 – $8.96
52 Week Range
$8.05 – $168.80
Volume
17,954
Avg. Volume
9,664
Market Cap
$2.61M
Beta (5Y Monthly)
1.05
PE Ratio (TTM)
--
EPS (TTM)
-$12.55
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$15.00

Profile: Biophytis S.A.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
22
CEO
Stanislas Veillet

Biophytis S.A. operates as a clinical-stage biotechnology firm dedicated to advancing therapeutic solutions aimed at decelerating degenerative processes and enhancing functional outcomes for individuals grappling with age-related illnesses. These therapies function by targeting and stimulating critical biological resilience pathways, which are designed to offer protection against and counteract the detrimental effects of various biological and environmental stressors contributing to age-associated pathologies. The company's flagship pharmaceutical candidate is Sarconeos (BIO101), an orally administered small molecule currently under development for addressing a spectrum of neuromuscular conditions, notably sarcopenia and Duchenne muscular dystrophy (DMD).

Earnings

DateEst.Actual
Sep 25, 2024–-$1.79
Apr 8, 2024-$0.30-$5.37Miss
Jul 21, 2023-$0.47-$0.20Beat
Apr 19, 2023-$1.12-$1.12Beat
Nov 1, 2022–-$17.55
May 26, 2022–-$32.27

Analyst view

Consensus price target
$15.00 ▲ +82.5%
Range $15.00 – $15.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on BPTS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.